Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Breast Cancer Survivors with Obesity – Semaglutide’s Impact on Preclinical Markers of Cardiovascular Disease

Award Number: K23HL183845
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 07/01/2026
PERIOD OF PERFORMANCE END DATE: 06/30/2031

Group Awards By:

View Award Description

Breast Cancer Survivors with Obesity – Semaglutide’s Impact on Preclinical Markers of Cardiovascular Disease - PROJECT SUMMARY/ABSTRACT Breast cancer survivors (BCS) face a significantly elevated risk of cardiovascular disease (CVD), the leading cause of non-cancer death in this population. Obesity, a major and often overlooked contributor, significantly increases this risk beyond the effects of cardiotoxic cancer treatments. While the GLP-1 receptor agonist semaglutide shows promise for CVD prevention in BCS with obesity due to its substantial weight loss and its cardioprotective effects in individuals with established CVD, this has not been investigated. This study aims to address this knowledge gap by conducting a 24-week randomized controlled trial (n=50) comparing lifestyle modification alone to lifestyle modification plus semaglutide in BCS with obesity and without CVD. The study will comprehensively assess semaglutide's effects on preclinical markers of CVD, including vascular function and circulating biomarkers. We will assess vascular function using pulse wave velocity, augmentation index, and reactive hyperemic index (Aim 1), and evaluate circulating biomarkers using targeted proteomics via protein extension assay (Aim 2). Integrating vascular function testing and proteomic analysis will elucidate how semaglutide protects against CVD. This will in turn inform the development of early disease-modifying interventions to improve long-term outcomes for this high-risk population. This K23 proposal will support Dr. Hurtado Andrade's career development as an independent physician- scientist specializing in cardiometabolic health. Building upon her established expertise in clinical endocrinology and basic sciences, this five-year program at Mayo Clinic will provide focused training in three key areas: (1) a Master's degree in Clinical and Translational Science, establishing a strong foundation in clinical research methodology; (2) hands-on experience in the design and execution of clinical trials utilizing preclinical CVD markers; and (3) advanced training in proteomic and biomarker analysis. This comprehensive training program directly addresses critical gaps in Dr. Hurtado Andrade's expertise, equipping her to lead research on obesity- targeted CVD prevention. She will receive expert mentorship from a distinguished team: Dr. Chrisandra Shufelt (vascular health in women), Dr. Andres Acosta (obesity management and precision medicine), and Dr. Rickey Carter (clinical trial design and execution and bioinformatics). By integrating innovative methodologies with a robust career development framework, this project will inform the development of targeted CVD prevention strategies in cancer survivorship, ultimately improving long-term health outcomes for millions of women. In kipping with the NHLBI’s mission, the findings will contribute to personalized approaches to CVD prevention, enhancing quality of life and longevity for this vulnerable group. Moreover, this research will establish a foundation for a future R01 application focused on large-scale clinical trials designed to optimize cardiometabolic health interventions in BCS and other high-risk populations.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $199,244 )
2026	2026	MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION)	4500 SAN PABLO RD S	JACKSONVILLE	FL	32224	DUVAL	USA	Cardiovascular Diseases Research	000	1	7/3/2026	NEW	$199,244
														Subtotal = $199,244

Grand Total All Awards = $199,244

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Breast Cancer Survivors with Obesity – Semaglutide’s Impact on Preclinical Markers of Cardiovascular Disease

Award Number: K23HL183845

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 07/01/2026

PERIOD OF PERFORMANCE END DATE: 06/30/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer